Fig 1.
BNCT, as a targeted radiotherapy, may selectively damage cancer cells while sparing normal ones.
Fig 2.
The advantage depth is the depth in the tissue at which the dose to the tumor equals the maximum dose to the normal tissue along the beam. The AD of THOR is 8.5 cm, which is deeper than the deepest depth of tumor tissue, providing therapeutic benefit.
Table 1.
Maximal tumor depths in each beam angle.
Fig 3.
Dose distribution of 2F (a), 3F (b) and 4F (c) irradiation.
A lower dose to normal brain may be obtained with 4F.
Fig 4.
Dose volume histograms (DVHs) of 2F (a), 3F (b) and 4F (c) irradiation for one representative case.
Table 2.
Patient number, age, and CTV dosimetric parameter of 2F, 3F, and 4F plans.
Table 3.
CTVmin/NTmax, HI, and beam-on time of 2F, 3F and 4F plans.
Table 4.
Volume, Dmean, Dmax, ID of NB, ON, CW and beam on time for 2F, 3F, and 4F plans.